![Anti-CD52 [Alemtuzumab (Campath-1H)] 抗体，orb348891，Biorbyt产品图](https://img1.dxycdn.com/p/s14/2026/0722/328/4013203418758089702.jpg)
- ￥7254
- Biorbyt
- orb348891
- 英国
- 2026年07月22日
- ELISA, FC, IHC-Fr, IHC-P, WB
- Human
- Human, Primate
企业认证
相关产品推荐更多 >
万千商家帮你免费找货
0 人在求购买到急需产品
相关阅读
AI 赋能培养基定制开发：CHO 培养基是如何实现产量提升Cytoscape 教程来了！快速实现顶刊同款通路网络图五大应用案例：Mustang Q 膜层析应用全解析1 个小工具，一次性搞定流程图、质粒图谱和信号通路图- 详细信息
- 文献和实验
- 技术资料
- 抗体名：
Anti-CD52 [Alemtuzumab (Campath-1H)] 抗体
- 抗体英文名：
Anti-CD52 [Alemtuzumab (Campath-1H)]
- 靶点：
CD52
- 浓度：
1 mg/ml
- 应用范围：
ELISA, FC, IHC-Fr, IHC-P, WB
- 宿主：
Human
- 适应物种：
Human, Primate
- 保质期：
12 months from date of receipt.
- 抗原来源：
详询
- 目录编号：
orb348891
- 级别：
科研
- 库存：
99
- 供应商：
Biorbyt
- 标记物：
Unconjugated
- 克隆性：
Monoclonal
- 保存条件：
详询
- 亚型：
Human IgG
- 免疫原：
详询
- 规格：
0.2 mg
描述: Rabbit monoclonal antibody to CD52
克隆号: Alemtuzumab (Campath-1H)
别名: CDW52; Cambridge pathology 1 antigen; Epididymal secretory protein E5; Human epididymis-specific protein 5; YTH66.9HL
免疫原: Human lymphocytes.
防腐剂: PBS with 0.02% Proclin 300.
纯度: Purified
特异性: Human CD52 antigen, also known as CAMPATH-1. CD52 is expressed at high density by lymphocytes, monocytes, eosinophils, thymocytes and macrophages. It is expressed by most lymphoid derived malignancies, although expression on myeloma cells is variable.
研究领域: Immunology & Inflammation
UniProt ID: P31358
保存条件: Maintain refrigerated at 2-8°C for up to 2 weeks. For long term storage store at -20°C in small aliquots to prevent freeze-thaw cycles.
备注: For research use only.
风险提示：丁香通仅作为第三方平台，为商家信息发布提供平台空间。用户咨询产品时请注意保护个人信息及财产安全，合理判断，谨慎选购商品，商家和用户对交易行为负责。对于医疗器械类产品，请先查证核实企业经营资质和医疗器械产品注册证情况。
文献和实验CD52 分子 常用单克隆抗体或代号： YTH66.9;(Campath- 1) 主要表达细胞： Leu,Eo [NL] 分子质量(kDa)和结构： gp25- 29 功 能： 补体介导溶解作用的靶分子 Aka Campath-1 CD52 antibodies are lytic for target cells, both with human complement and via antibody dependent cellular
Alemtuzumab (Campath), the humanized rat monoclonal antibody that targets the CD52 surface antigen, is currently used for treatment of patients with resistant chronic lymphocytic leukemia. Monitoring levels of the antibody in plasma/serum
The Application of Monoclonal Antibodies in the Treatment of Lymphoma
-CD20 and anti-CD52 (CAMPATH 1) mAb suggest, at least for certain neoplasms, that the situation may be changing (2 ,3 ). Stevenson and colleagues (personal communication) have recently achieved more than 70% complete responses in posttransplant
技术资料暂无技术资料 索取技术资料
